Alpha Tau Medical (DRTS) vs Nanobiotix S.A. (NBTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Tau Medical (DRTS) has outperformed Nanobiotix S.A. (NBTX) over the past year, gaining 245.0% versus a gain of 17.4%. Over five years, NBTX leads with a +92.0% price change compared with +44.1% for DRTS. Alpha Tau Medical is the larger company by market cap ($1.32 billion vs $1.25 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRTS | NBTX |
|---|---|---|
| Share price | $14.25 | $24.62 |
| Market cap | $1.32B | $1.25B |
| 1-day change | -1.59% | -2.42% |
| YTD return | +187.88% | +6.49% |
| 1-year return | +245.04% | +17.41% |
| 5-year return | +44.08% | +92.04% |
| EPS (TTM) | $-1.04 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.79 | $57.14 |
| 52-week low | $3.43 | $14.78 |
| Distance from 52-week high | -9.75% | -56.91% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +24.91% | +118.85% |
| Average volume | 568.24K | 149.07K |
| Shares outstanding | 92.48M | 50.92M |
| Employees | 121 | 100 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRTS has outperformed NBTX by 227.6 percentage points over the past year.
About Alpha Tau Medical
DRTS stock →Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Health Care · Medical/Dental Instruments · 121 employees
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
DRTS vs NBTX FAQ
Which is bigger, Alpha Tau Medical or Nanobiotix S.A.?
Alpha Tau Medical (DRTS) is larger, with a market capitalization of $1.32B compared with $1.25B for Nanobiotix S.A. (NBTX).
Which stock has performed better over the past year, DRTS or NBTX?
DRTS returned +245.04% over the past 12 months, compared with +17.41% for NBTX (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Tau Medical and Nanobiotix S.A. in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Alpha Tau Medical and Biotechnology: Pharmaceutical Preparations for Nanobiotix S.A..